HCPCS Level II code A9597 denotes a PET radiopharmaceutical used for diagnostic tumor identification when no more specific radiotracer code applies. This code matters nationally as PET imaging with specialized radiopharmaceuticals plays a central role in oncology staging, treatment planning, and response assessment. Accurate coding for tracers that lack dedicated codes affects clinical documentation, claims processing, and consistent national reporting for advanced imaging.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how A9597 is used clinically, the typical sites of service where these diagnostic agents are administered, and practical implications for billing and claims processing. The publication outlines benchmarking considerations, common billing modifiers relevant to component reporting, and areas where policy updates or payer-specific coverage rules could affect claim adjudication. Where input data is missing, the summary notes the absence rather than inferring specifics.

This national-level briefing is intended for revenue cycle professionals, hospital and imaging center administrators, and policy analysts who need a clear, focused reference on the clinical purpose and billing context of HCPCS Level II code A9597.